Bone Therapeutics SA: Information on the total number of voting rights and shares
23 Ottobre 2020 - 7:00AM
Bone Therapeutics SA: Information on the total number of voting
rights and shares
REGULATED INFORMATION
Gosselies, Belgium, 23 October
2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and
Paris: BOTHE), the cell therapy company established to address
unmet medical needs in orthopedics and other diseases, today
announces an increase in the total number of voting rights and
shares as a result of the issuance of new shares on 8 October
2020 following the conversion of convertible bonds issued in the
private placements on 7 March 2018 and 28 April 2020. The
following information is published in accordance with
Article 15 of the Belgian Law of 2 May 2007 on the
publication of major shareholdings in issuers whose shares are
admitted to trading on regulated market.
Total amount of share capital on 21 August 2020 |
EUR 6,059,582 |
Total number of shares with voting rights on 21 August
2020 |
11,859,871 |
Total number of new shares issued on 8 October 2020 |
209,416 |
Total amount of share capital on 8 October 2020 |
EUR 6,166,384 |
Total number of shares with voting rights on 8 October
2020 |
12,069,287 |
Total number of voting rights (denominator) on 8 October
2020 |
12,069,287 |
Total number of attributed warrants |
133,055 |
Total number of convertible bonds outstanding |
1,602 |
Total number of bond warrants and bond subscription commitments
outstanding |
2,035 |
Total number of shares with voting rights that could be issued
following the exercise of the attributed warrants, the bond
warrants and bond subscription commitments, and the conversion of
the convertible bonds |
2,956,553 (1) |
(1)
- 133,055 shares could be issued following the exercise of the
133,055 attributed warrants.
- 272,663 shares could be issued following the exercise and
conversion of the 2 convertible bonds and 240 bond warrants
outstanding, issued in the private placement on 7 March 2018. The
conversion is based on the conversion price of EUR 2.2189 (92%
of the Volume-Weighted-Averaged-Price of Bone Therapeutics’ shares
on 8 October 2020).
- 1,979,407 shares could be issued following the exercise and
conversion of 1,795 bond subscription commitments outstanding,
issued in the private placement on 28 April 2020. The
conversion is based on the conversion price of EUR 2.2671 (94%
of the Volume-Weighted-Averaged-Price of Bone Therapeutics’ shares
on 8 October 2020).
- 571,428 shares could be issued following the conversion of the
1,600 convertible bonds outstanding, issued in the private
placement on 6 May 2020. The conversion is based on the
predetermined conversion price of EUR 7.00.
About Bone Therapeutics
Bone Therapeutics is a leading biotech company
focused on the development of innovative products to address high
unmet needs in orthopedics and other diseases. The Company has a,
diversified portfolio of cell and biologic therapies at different
stages ranging from pre-clinical programs in immunomodulation to
mid-to-late stage clinical development for orthopedic conditions,
targeting markets with large unmet medical needs and limited
innovation.
Bone Therapeutics is developing an off-the-shelf
next-generation improved viscosupplement, JTA-004, which is
currently in phase III development for the treatment of pain in
knee osteoarthritis. Consisting of a unique combination of plasma
proteins, hyaluronic acid - a natural component of knee synovial
fluid, and a fast-acting analgesic, JTA-004 intends to provide
added lubrication and protection to the cartilage of the arthritic
joint and to alleviate osteoarthritic pain and inflammation.
Positive phase IIb efficacy results in patients with knee
osteoarthritis showed a statistically significant improvement in
pain relief compared to a leading viscosupplement.
Bone Therapeutics’ core technology is based on
its cutting-edge allogeneic cell therapy platform with
differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs)
which can be stored at the point of use in the hospital. Currently
in pre-clinical development, BT-20, the most recent product
candidate from this technology, targets inflammatory conditions,
while the leading investigational medicinal product, ALLOB,
represents a unique, proprietary approach to bone regeneration,
which turns undifferentiated stromal cells from healthy donors into
bone-forming cells. These cells are produced via the Bone
Therapeutics’ scalable manufacturing process. Following the CTA
approval by regulatory authorities in Europe, the Company is ready
to start the phase IIb clinical trial with ALLOB in patients with
difficult tibial fractures, using its optimized production process.
ALLOB continues to be evaluated for other orthopedic indications
including spinal fusion, osteotomy, maxillofacial and dental.
Bone Therapeutics’ cell therapy products are
manufactured to the highest GMP (Good Manufacturing Practices)
standards and are protected by a broad IP (Intellectual Property)
portfolio covering ten patent families as well as knowhow. The
Company is based in the BioPark in Gosselies, Belgium. Further
information is available at www.bonetherapeutics.com.
For further information, please
contact:
Bone Therapeutics SAMiguel
Forte, MD, PhD, Chief Executive OfficerJean-Luc Vandebroek, Chief
Financial OfficerTel: +32 (0)71 12 10
00investorrelations@bonetherapeutics.com
For Belgian Media and Investor
Enquiries:BepublicCatherine HaquenneTel: +32
(0)497 75 63 56catherine@bepublic.be
International Media Enquiries:Image Box
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Media and Investor
Enquiries:NewCap Investor Relations & Financial
CommunicationsPierre Laurent, Louis-Victor Delouvrier and
Arthur RouilléTel: +33 (0)1 44 71 94 94bone@newcap.eu
For US Media and Investor Enquiries:LHA
Investor RelationsYvonne BriggsTel: +1 310 691
7100ybriggs@lhai.com
Certain statements,
beliefs and opinions in this press release are forward-looking,
which reflect the Company or, as appropriate, the Company
directors’ current expectations and projections about future
events. By their nature, forward-looking statements involve a
number of risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome
and financial effects of the plans and events described herein. A
multitude of factors including, but not limited to, changes in
demand, competition and technology, can cause actual events,
performance or results to differ significantly from any anticipated
development. Forward looking statements contained in this press
release regarding past trends or activities should not be taken as
a representation that such trends or activities will continue in
the future. As a result, the Company expressly disclaims any
obligation or undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person’s officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.